<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Infection Immunity and Inflammation</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D0CA1C0D-F077-4E76-A7E0-16C152473284"><gtr:id>D0CA1C0D-F077-4E76-A7E0-16C152473284</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Brunskill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6A1D1FD5-9CEA-45CB-9BC7-A93B3EBC7E39"><gtr:id>6A1D1FD5-9CEA-45CB-9BC7-A93B3EBC7E39</gtr:id><gtr:firstName>Gary</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Willars</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500688"><gtr:id>D6EF821D-B602-4F41-A4A7-F64B5E17177A</gtr:id><gtr:title>Defining the cellular mechanisms of C-peptide in the kidney: Understanding renoprotective effects in diabetic nephropath</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500688</gtr:grantReference><gtr:abstractText>Patients with diabetes have to live with a chronic illenss complicated by many health problems and often a premature death. Many patients suffer kidney failure and require dialysis treatment as a result of their diabetes. The number of patients with diabetes is rising quickly. Although current treatments are helpful they are by no means perfect. This research seeks to examine the potential for C-peptide to act as an additional treatment for diabetes. C-peptide is released from the pancreas gland with insulin but has previously been thought to have no function. New information however suggests that C-peptide may in fact have important effects in kidney cells that may protect them against diabetes. This research will examine these cellular phenomena in kidney cells growing in culture and in rats with diabetes. It is hoped that the results may justify extending to clinical trials to human subjects with diabetes.</gtr:abstractText><gtr:technicalSummary>Diabetes is a growing international public health problem. In terms of complications, diabetic nephropathy imposes a considerable burden upon individual patients and society. Diabetic nephropathy now accounts for a majority of patients starting dialysis. New treatments are urgently needed. A growing body of evidence suggests that C-peptide, previously believed to be inert, may have significant cell signalling capabilities and the potential for development as a therapeutic agent in diabetic nephropathy. Particularly, data from our laboratory demonstrates that C-peptide activates multiple signalling pathways in kidney proximal tubular cells including activation of the transcription factor PPAR??. 
The aim of this study is to further characterise signalling pathways activated by C-peptide in proximal tubular cells, in particular focussing on interactions with the insulin receptor. In addition the ability of C-peptide to block or abrogate the deleterious effects of high glucose in the kidney will be studied. Specifically the effect of C-peptide on proximal tubular cell secretion of TGF?O1 and matrix proteins will be studied, as will C-peptide effects on transdifferentiation of tubular cells to myofibroblast type cells. Furthermore gene chip analysis will be performed to characterise changes in gene expression occurring in proximal tubular cells in response to C-peptide.
The in-vitro studies will be accompanied by an in-vivo of C-peptide in streptozotocin rats. After a preliminary study to determine an optimum time course, animals will be administered either insulin or insulin with C-peptide in a long term study of diabetes to examine whether potentially protective effects of C-peptide seen in-vitro are paralleled by similar events in-vivo.
It is hoped that the results of these experiments will justify the development of a clinical trial of C-peptide in diabetic patients.</gtr:technicalSummary><gtr:fund><gtr:end>2009-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>210333</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Project Grant</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>A65F7025-8391-4D38-9E95-466F58239D33</gtr:id><gtr:outcomeId>iJBjVET8avn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:fundingRef>11/0004235</gtr:fundingRef><gtr:id>0F87AFA8-BF55-40AE-948A-04F4B0C20968</gtr:id><gtr:outcomeId>svbvbvN8Tyb</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>microarray data derived from kidney cells treated with C-peptide</gtr:description><gtr:id>2290D0AC-47D8-476A-916F-A6CC024F8EC5</gtr:id><gtr:impact>this data is in the process of publication and will be published on journal website</gtr:impact><gtr:outcomeId>586E6531240</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>gene microarray</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6E26965B-368E-4E56-A588-6425B0D936DE</gtr:id><gtr:title>Intracellular signalling by C-peptide.</gtr:title><gtr:parentPublicationTitle>Experimental diabetes research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002b10326223d68386b4aeaf428240f9"><gtr:id>002b10326223d68386b4aeaf428240f9</gtr:id><gtr:otherNames>Hills CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1687-5214</gtr:issn><gtr:outcomeId>2D03E74CC11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>504E5EDE-E3CE-4DAA-9A7A-A43AEDCC9E07</gtr:id><gtr:title>C-peptide and diabetic kidney disease.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55949ba854e10bfc7d4018a9d4321d78"><gtr:id>55949ba854e10bfc7d4018a9d4321d78</gtr:id><gtr:otherNames>Brunskill NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn><gtr:outcomeId>58c689188708d6.97630054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C36BFF18-35BA-4876-91D0-647B4B73ECE4</gtr:id><gtr:title>C-peptide as a therapeutic tool in diabetic nephropathy.</gtr:title><gtr:parentPublicationTitle>American journal of nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002b10326223d68386b4aeaf428240f9"><gtr:id>002b10326223d68386b4aeaf428240f9</gtr:id><gtr:otherNames>Hills CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0250-8095</gtr:issn><gtr:outcomeId>XhJV2DDYCPV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>599B6FF7-465F-4676-B6E5-91E05EA80FB8</gtr:id><gtr:title>C-peptide reverses TGF-beta1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Renal physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002b10326223d68386b4aeaf428240f9"><gtr:id>002b10326223d68386b4aeaf428240f9</gtr:id><gtr:otherNames>Hills CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1522-1466</gtr:issn><gtr:outcomeId>234F99418EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73739A9A-56A1-46EE-A7C4-1F7960524882</gtr:id><gtr:title>Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32f895cec5735d8f2f0974d6f9692338"><gtr:id>32f895cec5735d8f2f0974d6f9692338</gtr:id><gtr:otherNames>Burton JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>545a5fa780f8f2.87212667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1E5C41E-14B5-4666-9054-E28B54329EA5</gtr:id><gtr:title>Cellular and physiological effects of C-peptide.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002b10326223d68386b4aeaf428240f9"><gtr:id>002b10326223d68386b4aeaf428240f9</gtr:id><gtr:otherNames>Hills CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>549E7932403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC1789CE-3CB9-4EC4-8B45-2CA5440314EF</gtr:id><gtr:title>Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24e0b6bd68002f060557221b598f7af1"><gtr:id>24e0b6bd68002f060557221b598f7af1</gtr:id><gtr:otherNames>Major RW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>58c689726b71b3.21394065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9990A08B-C8F0-4F80-A10D-6CC5531F9D11</gtr:id><gtr:title>Proinsulin C-peptide antagonizes the profibrotic effects of TGF-beta1 via up-regulation of retinoic acid and HGF-related signaling pathways.</gtr:title><gtr:parentPublicationTitle>Molecular endocrinology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002b10326223d68386b4aeaf428240f9"><gtr:id>002b10326223d68386b4aeaf428240f9</gtr:id><gtr:otherNames>Hills CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0888-8809</gtr:issn><gtr:outcomeId>iF7gJNHAsgi</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500688</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>